Tests azithromycin in children hospitalized with severe asthma
Studies azithromycin's effects on the immune system in children with critical asthma.
Plain-language title generated from the registry record
Registry title: Azithromycin for Critical Asthma - Pediatrics
Key facts
- Where
- St. Petersburg, United StatesSee the site
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 3 and 17 years old?
Source: NCT06223828, who can take part
Where in United States
- Johns Hopkins All Children's HospitalSt. Petersburg, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Johns Hopkins All Children's Hospital
- Trial code
- NCT06223828
- Record updated
- 11 August 2026
- Original description
The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.Read full original descriptionShow less
Azithromycin as Immunomodulation Among Children Hospitalized for Critical Asthma: A Prospective, Open-Label, Non-Randomized, Interventional Study With Parallel Biospecimen Banking
The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.
Inclusion: Age 3-17 years; Admission to the PICU; Primary diagnosis of critical asthma; Prescription for continuous inhaled beta-agonist therapy and/or intravenous (IV) beta-agonist therapy; Prescription for intravenous systemic corticosteroids.
Exclusion: Concomitant respiratory pathology including Acute Chest Syndrome, Interstitial Lung Disease, Cystic Fibrosis, and pulmonary hypertension; Critical Congenital Heart Disease Unrepaired; Past Medical History of Prolonged QT Syndrome or Arrhythmias; Tracheostomy Dependence at Admission; Ongoing Exposure to Azithromycin or Macrolide Antibiotics for any indication.